Form 4: Axsome Therapeutics Executive Ari Maizel Reports Stock Option and Unit Awards

Chief Commercial Officer Ari Maizel reports the acquisition of stock options, restricted stock units, and performance stock units in Axsome Therapeutics.

Summary

• Ari Maizel, Chief Commercial Officer of Axsome Therapeutics, reported transactions related to the company's stock.
• On February 21, 2025, Maizel acquired options to buy 7,816 shares of common stock at $137.75 per share, which vest quarterly over four years.
• Maizel also acquired 7,740 restricted stock units (RSUs) that vest over four years, with 25% vesting after one year and the remainder in three equal annual installments.
• Vested RSU shares will be delivered upon a change in control, separation of service, or seven years from the grant date.
• Additionally, Maizel acquired 7,740 performance stock units (PSUs) that vest upon achievement of certain financial, regulatory, and developmental milestones.
• The reporting person directly owns 7,816 employee stock options, 7,740 restricted stock units and 7,740 performance stock units.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating a stable and incentivized management structure. The sentiment is neutral to slightly positive as it suggests alignment of executive interests with company performance.

Future Outlook

The vesting of the stock options, RSUs, and PSUs is contingent upon continued service and/or achievement of specific milestones over the next four years.

Industry Context

This filing is a routine disclosure of executive compensation in the form of stock options and units, common in the pharmaceutical industry to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Stock option grants and RSU/PSU awards are standard components of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and performance milestones associated with these grants are typically aligned with the company's long-term strategic goals and regulatory milestones.

Stakeholder Impact

• The equity grants aim to align management's interests with those of shareholders by incentivizing performance and long-term value creation.
• Employees may be indirectly impacted as executive performance can influence overall company success.

Key Dates